BEAM

#1661
Beam Therapeutics Inc. Common Stock
30.30 USD
+0.40%
Sector: Healthcare
Base: USD
Profit Currency: USD
Daily Range
30.30
30.30
Year Range
15.35
36.44
Daily Change
+0.40%
Monthly Change
+17.90%
6 month change
+18.08%
Year Change
+80.57%
Previous Close
30.18
Open
30.30
Bid
Ask
Low
30.30
High
30.30
Volume
118
Open full chart

Financials

Overview Statement Statistics Dividends
Quarterly Annual
  • Market Capitalization 3.09 B
  • Employee 511
  • Founded 2017
  • CEO John Evans
  • Website www.beamtx.com
  • Headquarter Delaware, United States
  • FIGI BBG00KXC8646
  • Industry Technology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-34.22
Price to sales ratio
19.62

Beam Therapeutics Inc

Beam Therapeutics Inc. is an American biotechnology company conducting research in the field of gene therapies and genome editing. The company is headquartered in Cambridge, Massachusetts. In the development of therapies, the company relies on CRISPR base editing and prime editing, whereby single nucleotides in a DNA sequence can be enzymatically modified without producing double-strand breaks.

News